NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

biosect: I agree with you. As I've said before, the fact the upcoming journal article with be authored by a number of researchers from the various institutions that conducted the L trial who have no direct affiliation with the company, who have first hand knowledge, and who are respected in their field, will be so much more bulletproof than a study presented by Dr. Bosch or a PR from the company. An attack on the journal article would become an attack on the journal, the peer reviewer team, the researchers, and the first-hand, not speculative, observations that the researchers present.
Taken a few steps further, when approval comes, BP can not and will not choose to ignore or downplay DCVax-L. They'll be lining up to test combo treatments. CAR-T needs help, and DCVax can provide it. Legitimate consumer publications will seize on the DCVax story, and the tide will turn rather quickly to the point that the AFs of the world who choose to continue deriding a clear godsend to patients will look to most, if not all, like the absolute fools that they are.
This is all IMO, but it happens also to be true.